scholarly journals Feasibility of common bibliometrics in evaluating translational science

2017 ◽  
Vol 1 (1) ◽  
pp. 45-52 ◽  
Author(s):  
M. Schneider ◽  
C. M. Kane ◽  
J. Rainwater ◽  
L. Guerrero ◽  
G. Tong ◽  
...  

IntroductionA pilot study by 6 Clinical and Translational Science Awards (CTSAs) explored how bibliometrics can be used to assess research influence.MethodsEvaluators from 6 institutions shared data on publications (4202 total) they supported, and conducted a combined analysis with state-of-the-art tools. This paper presents selected results based on the tools from 2 widely used vendors for bibliometrics: Thomson Reuters and Elsevier.ResultsBoth vendors located a high percentage of publications within their proprietary databases (>90%) and provided similar but not equivalent bibliometrics for estimating productivity (number of publications) and influence (citation rates, percentage of papers in the top 10% of citations, observed citations relative to expected citations). A recently available bibliometric from the National Institutes of Health Office of Portfolio Analysis, examined after the initial analysis, showed tremendous potential for use in the CTSA context.ConclusionDespite challenges in making cross-CTSA comparisons, bibliometrics can enhance our understanding of the value of CTSA-supported clinical and translational research.

2010 ◽  
Vol 24 (1) ◽  
pp. 9-24 ◽  
Author(s):  
Nancy Fugate Woods ◽  
Diane L. Magyary

The heightened demand for benefit from scientific contributions has driven scientific initiatives such as the NIH Roadmap, the recently established Clinical Translational Science Awards, and requests for applications for funding by the National Institutes of Health (NIH) and Agency for Health Research and Quality (AHRQ) to support studies of translational efforts. Our article focuses on a rapidly developing area—translational research—and the value, if not necessity, of nursing’s contributions to interdisciplinary efforts. Our objectives are to: 1. Relate the changing nature of research (and clinical practice) to the need for interdisciplinary efforts in translational research; 2. Delineate the skills necessary for translation of research to clinical and community-based practice; 3. Review nursing’s contributions to national interdisciplinary initiatives; 4. Identify critical areas for nursing leadership in translational research and consequences of our absence from these efforts; and 5. Propose a translational research agenda for nursing.


2019 ◽  
Vol 4 (1) ◽  
pp. 43-52 ◽  
Author(s):  
Christine A. Sorkness ◽  
Linda Scholl ◽  
Alecia M. Fair ◽  
Jason G. Umans

AbstractIntroduction:NIH Clinical and Translational Science Awards (CTSAs) include KL2 mentored career development awards for faculty commencing clinical and translational research. A survey of KL2 leaders revealed program practices, curricular elements and compelling data about scholar characteristics and outcomes.Methods:We conducted a literature review, framed the survey construct, and obtained input from across the CTSA consortium. A REDCap survey was emailed in fall 2016 to 61 active programs.Results:Fifty-five programs (90.2%) responded. Respondents had been funded from 3 to 11 years, including 22 “mature” hubs funded for ≥8 years. Program cohort sizes were 56% “small”, 22% “medium”, and 22% “large.” Hubs offer extensive competency-aligned training opportunities relevant to clinical and translational research, including graduate degrees, mentorship, and grant-writing. Seventy-two percent of hubs report parallel “KL2-equivalent” career development programs. All hubs share their training and facilitate intermingling with other early stage investigators. A total of 1,517 KL2 scholars were funded. KL2 awardees are diverse in their disciplines, research projects, and representation; 54% are female and 12% self-identified as underrepresented in biomedical research. Eighty-seven percent of scholars have 2–3 mentors and are currently supported for 2–3 years. Seventy-eight percent of alumni remain at CTSA institutions in translational science. The most common form of NIH support following scholars’ KL2 award is an individual career development award.Conclusions:The KL2 is a unique career development award, shaped by competency-aligned training opportunities and interdisciplinary mentorship that inform translational research pathways. Tracking both traditional and novel outcomes of KL2 scholars is essential to capture their career trajectories and impact on health.


Author(s):  
Kelli Qua ◽  
Clara M. Pelfrey

Abstract Introduction: Evaluating clinical and translational research (CTR) mentored training programs is challenging because no two programs are alike. Careful selection of appropriate metrics is required to make valid comparisons between individuals and between programs. The KL2 program provides mentored-training for early-stage CTR investigators. Clinical and Translational Awards across the country have unique KL2 programs. The evaluation of KL2 programs has begun to incorporate bibliometrics to measure KL2 scholar and program impact. Methods: This study investigated demographic differences in bibliometric performance and post-K award funding of KL2 scholars and compared the bibliometric performance and post-K award federal funding of KL2 scholars and other mentored-K awardees at the same institution. Data for this study included SciVal and iCite bibliometrics and National Institutions of Health RePORTER grant information for mentored-K awardees (K08, K23, and KL2) at Case Western Reserve University between 2005 and 2013. Results: Results showed no demographics differences within the KL2 program scholars. Bibliometric differences between KL2 and other mentored-K awardee indicated an initial KL2 advantage for the number of publications at 5 years’ post-matriculation (i.e., the start of the K award). Regression analyses indicated the number of initial publications was a significant predictor of federal grant funding at the same time point. Analysis beyond the 5-year post-matriculation point did not result in a sustained, significant KL2 advantage. Conclusions: Factors that contributed to the grant funding advantage need to be determined. Additionally, differences between translational and clinical bibliometrics must be interpreted with caution, and appropriate metrics for translational science must be established.


2010 ◽  
Vol 85 (3) ◽  
pp. 463-469 ◽  
Author(s):  
Steven E. Reis ◽  
Lars Berglund ◽  
Gordon R. Bernard ◽  
Robert M. Califf ◽  
Garret A. FitzGerald ◽  
...  

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 11026-11026
Author(s):  
Aron Simkins ◽  
Michael Lee ◽  
Wencesley A. Paez ◽  
Cecilia Arana Yi ◽  
Heidi E. Kosiorek ◽  
...  

11026 Background: The Clinical and Translational Science Award (CTSA) Program currently supports more than 50 leading medical research institutions in the U.S. with the aims of training, promoting and developing future translational science researchers, with particular emphasis on advanced Clinical and Translational Research (CTR) education. No prior studies have evaluated career development in oncologists who have completed CTR training. The objective of this study is to examine the impact of advanced CTR training on career development, return-on-investment and research productivity in Oncology specialties. Methods: With IRB approval, we conducted a survey study of U.S.-based Hematology/Oncology (H/O), Radiation Oncology (RO), and Surgical Oncology (SO) members of the American Society of Clinical Oncology who completed CTR training. Data was anonymized and collected through Research Electronic Data Capture (REDCap). Outcomes were compared using Chi-square test for frequency data. Results: We received 225 survey responses (62.1% H/O, 23.3% RO, 13.2% SO, 1.4% others). About 28.4% (n = 64) of the respondents had a PhD or Master's degree in CTR (Group A) compared to 71.6% (n = 161) with graduate certificates or non-degree granting courses in CTR (Group B). Specialty ratio was equally distributed between both groups. Overall, 79.7% vs 57.5%; P < 0.001 of respondents worked in academia, of which 55.2% had tenure track positions. Over 49 different CTSA Programs throughout the U.S. were represented. In terms of impact with new research projects, the ability to secure funding and opportunities for multidisciplinary collaboration, satisfaction with CTR training was higher among Group A compared with Group B (P < 0.001; P < 0.01; P < 0.01 respectively). In terms of research output, higher satisfaction was seen in Group A (67.2% vs 47.4%; P < 0.01), however total publications per year were not statistically significant (P = 0.135). Usefulness of a CTR degree on career advancement, a difference of 50.0% vs 19.1%; P < 0.001 was noted. Similarly, usefulness regarding new job opportunities and return-on-investment also favored Group A (P < 0.001). Overall satisfaction with training was significantly higher in Group A (73.4% vs 48.7%; P = 0.004). Conclusions: This study is the first to report satisfaction ratings for CTR training among oncology specialties. Although no significant difference was observed in terms of publication output, those with higher levels of advanced degrees were more satisfied with their CTR training, and viewed it as more impactful to career advancement and research productivity. The evidence presented is useful for informing career development for oncology residents and fellows offered CTR degrees during their training.


2019 ◽  
Vol 4 (2) ◽  
pp. 81-89 ◽  
Author(s):  
Linda B. Cottler ◽  
Alan I. Green ◽  
Harold Alan Pincus ◽  
Scott McIntosh ◽  
Jennifer L. Humensky ◽  
...  

AbstractThe opioid crisis in the USA requires immediate action through clinical and translational research. Already built network infrastructure through funding by the National Institute on Drug Abuse (NIDA) and National Center for Advancing Translational Sciences (NCATS) provides a major advantage to implement opioid-focused research which together could address this crisis. NIDA supports training grants and clinical trial networks; NCATS funds the Clinical and Translational Science Award (CTSA) Program with over 50 NCATS academic research hubs for regional clinical and translational research. Together, there is unique capacity for clinical research, bioinformatics, data science, community engagement, regulatory science, institutional partnerships, training and career development, and other key translational elements. The CTSA hubs provide unprecedented and timely response to local, regional, and national health crises to address research gaps [Clinical and Translational Science Awards Program, Center for Leading Innovation and Collaboration, Synergy paper request for applications]. This paper describes opportunities for collaborative opioid research at CTSA hubs and NIDA–NCATS opportunities that build capacity for best practices as this crisis evolves. Results of a Landscape Survey (among 63 hubs) are provided with descriptions of best practices and ideas for collaborations, with research conducted by hubs also involved in premier NIDA initiatives. Such collaborations could provide a rapid response to the opioid epidemic while advancing science in multiple disciplinary areas.


2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. 367-368
Author(s):  
Kamal Masaki ◽  
Tim Donlon ◽  
Donald Willcox ◽  
Brian Morris ◽  
Richard Allsopp ◽  
...  

Abstract sKuakini Medical Center (Kuakini) is establishing an interdisciplinary Hawai’i-based Center of Biomedical Research Excellence (COBRE) for clinical and translational research on aging. - Specific Aim 1: Create a world class, innovative, interdisciplinary Center for Translational Research on Aging by building on the existing rare and valuable Kuakini Honolulu Heart Program (Kuakini HHP) and its related studies and research infrastructure. - Specific Aim 2: Advance the genomic, biological and clinical science of aging, and enhance the world class character of our Center, by enlisting accomplished senior scientists to mentor promising Hawaii-based new investigators in interdisciplinary aging research and career development. - Specific Aim 3: Elevate the capacity of our Center by: i) creating a state-of-the-art Clinical and Translational Core, and ii) collaborating with other Centers of Biomedical Research Excellence. This presentation will briefly introduce the Center and discuss its aims, research strategy, and future plans.


Sign in / Sign up

Export Citation Format

Share Document